US FDA Approves Gilead’s Twice-Yearly Injection for HIV Prevention

In a significant advancement for HIV prevention, the US Food and Drug Administration (FDA) has granted approval to Gilead Sciences for its innovative twice-yearly injection designed to reduce the risk of acquiring HIV. The announcement, made on June 18, 2025, marks a major leap forward in the fight against HIV/AIDS, offering a more convenient and effective alternative to daily oral medications1.

The newly approved long-acting injectable is expected to improve adherence among individuals at high risk of HIV, as it only requires administration every six months. This development comes at a crucial time, as public health experts continue to seek new strategies to curb the spread of HIV, especially in populations where daily pill regimens pose challenges.

Gilead’s injection leverages advanced pharmaceutical technology to maintain therapeutic drug levels in the body over extended periods, providing sustained protection. The approval is based on robust clinical trial data demonstrating the injection’s safety and efficacy in preventing HIV infection.

Industry analysts suggest that this approval could have a transformative impact on HIV prevention programs globally, potentially reducing new infections and easing the burden on healthcare systems. The injection is expected to be available to eligible patients in the coming months, following final regulatory reviews and distribution arrangements.

Disclaimer:
This news article is based on information sourced from Reuters as of June 18, 2025, and additional context from related pharmaceutical industry updates. While every effort has been made to ensure accuracy, the article may not reflect the most current developments after publication. Readers are advised to consult official sources for the latest information. The article does not constitute medical advice. Always consult a healthcare professional before making decisions related to medical treatment or prevention.
(Note: The provided source link is for reference; however, the article is not a direct reproduction of the Reuters content.)